Eliminating the public health threat of viral hepatitis in situation with both opportunities and challenges

YANG Shi-gui

doi:10.16462/j.cnki.zhjbkz.2021.07.002

Volume 25 Issue 7

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(7): 749-752

YANG Shi-gui. Eliminating the public health threat of viral hepatitis in situation with both opportunities and challenges[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(7): 749-752. doi: 10.16462/j.cnki.zhjbkz.2021.07.002

Citation:

YANG Shi-gui. Eliminating the public health threat of viral hepatitis in situation with both opportunities and challenges[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(7): 749-752. doi: 10.16462/j.cnki.zhjbkz.2021.07.002

Citation:

PDF( 823 KB)

Eliminating the public health threat of viral hepatitis in situation with both opportunities and challenges

doi: 10.16462/j.cnki.zhjbkz.2021.07.002

YANG Shi-gui^,

The First Affiliated Hospital, College of Medicine, Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases Zhejiang University, National Clinical Research Center for Infectious Diseases Zhejiang University, Hangzhou 310003, China

Funds:

National Natural Science Foundation of China U1611264

National Natural Science Foundation of China 81672005

National Science and Technology Major Project 2018ZX10715-014-002

National Science and Technology Major Project 2014ZX10004008

Fund of Young and middle-aged scientific and technological innovation leaders of the Ministry of Science and Technology 2017RA2120

More Information

Corresponding author: YANG Shi-gui, E-mail: yangshigui@zju.edu.cn
Received Date: 2021-05-23
Rev Recd Date: 2021-06-23

Available Online: 2021-08-13

Publish Date: 2021-07-10

Abstract

Abstract

In the past three decades, with the implementation of vaccinating against hepatitis A, hepatitis B and hepatitis E, it has achieved remarkable achievements in controlling incidence and prevalence of viral hepatitis. At the same time, the successful development of direct-acting antiviral agents (DAA) for hepatitis C also brings hope for eliminating the public health threat of hepatitis C. However, due to the low rate of early diagnosis of viral hepatitis, the uneven availability of vaccines and antiviral drugs among countries or regions, and the lack of awareness of the harmfulness of viral hepatitis, the disease burden of viral hepatitis is still heavy. It remains a severe public health problem in global. Therefore, to eliminate the public health threat of viral hepatitis, it is necessary to improve the existing coping strategies, strengthen vaccine immunization, expand screening, and popularize antiviral treatment and other comprehensive measures. This article discusses the epidemic situation of viral hepatitis in China and the world, the current situation of prevention and treatment, the goal of WHO to eliminate the public health threat of viral hepatitis, and the action plan adopted.
- Viral hepatitis,
- Disease burden,
- Prevention and control

FullText(HTML)

References(23)

References

[1]	Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1): 151-171. DOI: 10.1016/j.jhep.2018.09.014.
[2]	Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013[J]. Lancet, 2016, 388(10049): 1081-1088. DOI: 10.1016/S0140-6736(16)30579-7.
[3]	World Health Organization. Draft global health sector strategy on viral hepatitis, 2016-2021. [EB/OL]. (2016-06-01)[2021-05-01]. https://www.emcdda.europa.eu/system/files/attachments/9478/WHO-HIV-2016.06-eng.pdf.
[4]	GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1151-1210. DOI: 10.1016/S0140-6736(17)32152-9.
[5]	World Health Organization. WHO position paper on hepatitis A vaccines - June 2012[J]. Wkly Epidemiol Rec, 2012, 87(28/29): 261-276.
[6]	Alventosa MC, Urquijo PJ, Diago MM. An outbreak of acute hepatitis due to the hepatitis A virus in 2017: are we witnessing a change in contagion risk factors?[J]. Rev Esp Enferm Dig, 2018, 110(10): 675-676. DOI: 10.17235/reed.2018.5633/2018.
[7]	Wang H, Gao P, Chen WX, et al. Changing epidemiological characteristics of Hepatitis A and warning of Anti-HAV immunity in Beijing, China: a comparison of prevalence from 1990 to 2017[J]. Hum Vaccin Immunother, 2019, 15(2): 420-425. DOI: 10.1080/21645515.2018.1529128.
[8]	Croker C, Hathaway S, Marutani A, et al. Outbreak of hepatitis A virus infection among adult patients of a mental hospital - Los Angeles County, 2017[J]. Infect Control Hosp Epidemiol, 2018, 39(7): 881. DOI: 10.1017/ice.2018.77.
[9]	Souto FJD, de Brito WI, Fontes CJF. Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil[J]. Vaccine, 2019, 37(6): 771-775. DOI: 10.1016/j.vaccine.2018.12.054.
[10]	Örmeci N, Malhan S, Balik I, et al. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey[J]. Hepatol Int, 2017, 11(6): 509-516. DOI: 10.1007/s12072-017-9820-3.
[11]	陈园生, 王旭霞, 尚鹏辉, 等. 中国人群乙型肝炎病毒表面抗原流行规律变迁的初步研究[J]. 中华实验和临床感染病杂志(电子版), 2007, 1(1): 20-21. DOI: 10.3969/j.issn.1674-1358.2007.01.008. Chen YS, Wang XX, Shang PH. The study of tendency of hepatitis B virus surface antigen in Chinese population[J]. Chin J Exp Clin Infect Dis (Electronic Version), 2007, 1(1): 20-21. DOI: 10.3969/j.issn.1674-1358.2007.01.008.
[12]	Xia GL, Liu CB, Cao HL, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992[J]. International Hepatology Communications, 1996, 5(1): 62-73. DOI: 10.1016/S0928-4346(96)82012-3.
[13]	Liang XF, Bi SL, Yang WZ, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27(47): 6550-6557. DOI: 10.1016/j.vaccine.2009.08.048.
[14]	Dienstag JL. Hepatitis B virus infection[J]. N Engl J Med, 2008, 359(14): 1486-1500. DOI: 10.1056/NEJMra0801644.
[15]	Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2(3): 161-176. DOI: 10.1016/S2468-1253(16)30181-9.
[16]	Botelho-Souza LF, Vasconcelos MPA, Dos Santos AO, et al. Hepatitis delta: virological and clinical aspects[J]. Virol J, 2017, 14(1): 177. DOI: 10.1186/s12985-017-0845-y.
[17]	Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
[18]	Li PF, Liu JY, Li Y, et al. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis[J]. Liver Int, 2020, 40(7): 1516-1528. DOI: 10.1111/liv.14468.
[19]	World Health Organization. Global hepatitis report, 2017[EB/OL]. (2017-01-01)[2021-05-01]. https://extranet.who.int/iris/restricted/bitstream/handle/10665/255016/9789241565455-eng.pdf.
[20]	Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study[J]. Lancet Infect Dis, 2016, 16(12): 1399-1408. DOI: 10.1016/S1473-3099(16)30204-3.
[21]	Singer AW, Reddy KR, Telep LE, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study[J]. Aliment Pharmacol Ther, 2018, 47(9): 1278-1287. DOI: 10.1111/apt.14593.
[22]	Tan MJ, Bhadoria AS, Cui FQ, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(2): 106-119. DOI: 10.1016/S2468-1253(20)30307-1.
[23]	Zhang Q, Qi WQ, Wang X, et al. Epidemiology of hepatitis B and hepatitis C infections and benefits of programs for hepatitis prevention in Northeastern China: a cross-sectional study[J]. Clin Infect Dis, 2016, 62(3): 305-312. DOI: 10.1093/cid/civ859.